Dendrimer Drug Delivery (DEP®)
Starpharma’s dendrimers can be used to enhance the properties of other drugs. The approach is known as “drug delivery” because it is about working to ensure that the drug is delivered to the right part of the body at the right time. Starpharma's dendrimer drug delivery technology is known as DEP®.
Starpharma uses DEP® both in its own drug development pipeline and with partners. The most advanced DEP® product in Starpharma's pipeline is DEP® docetaxel which is in Phase 2 clinical trials.
More information on Starpharma's internal clinical candidates:
- Improving Efficacy
- Reducing toxic side effects of drugs
- Extending the duration of activity of the drug in the body
- Targeting drugs to Organs, Tissues or Molecular Receptors
- Increasing Solubility
Starpharma has applied this technology in its own development programs (such as DEP® docetaxel) and in partnership with pharmaceutical companies including AstraZeneca and a number of other undisclosed partners. The technology has applicability for many different diseases.